Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Contineum Therapeutics (CTNM) Equity Average (2023 - 2026)

Contineum Therapeutics' Equity Average history spans 4 years, with the latest figure at $255.5 million for Q1 2026.

  • Quarterly Equity Average rose 33.49% to $255.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $255.5 million through Mar 2026, up 33.49% year-over-year, with the annual reading at $229.5 million for FY2025, 252.77% up from the prior year.
  • Equity Average came in at $255.5 million for Q1 2026, up from $220.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $255.5 million in Q1 2026 to a low of -$76.4 million in Q2 2023.
  • The 4-year median for Equity Average is $177.0 million (2025), against an average of $103.3 million.
  • Year-over-year, Equity Average surged 466.91% in 2024 and then decreased 17.74% in 2025.
  • Contineum Therapeutics' Equity Average stood at -$64.5 million in 2023, then surged by 416.31% to $204.1 million in 2024, then grew by 8.12% to $220.7 million in 2025, then rose by 15.76% to $255.5 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Equity Average are $255.5 million (Q1 2026), $220.7 million (Q4 2025), and $175.9 million (Q3 2025).